Company: Roche / Genentech
Tags: pipeline, rumors
The writing has been on the wall for a while with Tecentriq in lung. With the bladder cancer indication pulled and competition from Keytruda and Opdivo intensifying, it feels like Roche is slowly deprioritizing it. My DM won't say anything definitive but the investment in pull-through support has visibly dropped. Sample allocation is down, speaker programs have dried up. Anyone else sensing a resource shift toward Alecensa and the newer stuff? I'm not panicking but I'm keeping my options open. Would be good to know if others in the oncology field force are getting similar signals from leadersh
20 upvotes · 5 comments